类有机物
精密医学
表观遗传学
计算生物学
癌症
医学
药物发现
再生医学
生物
精确肿瘤学
药物反应
个性化医疗
神经科学
生物信息学
癌症研究
干细胞
癌症干细胞
药物开发
药品
病理
基因
细胞生物学
遗传学
药理学
作者
Xinyi Xia,Fēi Li,Jinzhi He,Rebiguli Aji,Dong Gao
标识
DOI:10.1016/j.canlet.2019.04.039
摘要
Organoid technology has been remarkably improved over the last decade. Various organoids have been derived from different types of tissues and recapitulate their organ-specific gene expression signatures, particular tissue spatial structures and functions of their original tissue. The patient-derived organoids (PDOs) have been used to elucidate crucial scientific questions, including the relationships between genetic/epigenetic alterations and drug responses, cell plasticity during disease progressions, and mechanisms of drug resistances. With the great expectations, PDOs will be widely used to facilitate the personalized medical decisions, which have the potential to profoundly improve patient outcomes. In this review, we will discuss the developmental details, current achievements, applications and challenges of organoid technology in precision cancer medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI